Skin appendage disorders · 2026
Poor Therapeutic Response in Female Pattern Hair Loss: Mechanisms and a Practical Framework for Clinical Management.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Haoyu, Zhang Xin, Yang Han, Li Jiaxin, Yang Jing
Аннотация
BACKGROUND: Female pattern hair loss (FPHL) is the most common cause of hair loss in women, yet therapeutic responses remain highly variable. A substantial proportion of patients experience persistent hair thinning or limited hair density improvement despite standard therapies, and current guidelines provide limited guidance for managing patients with poor therapeutic response.
SUMMARY: This review summarizes the major determinants of poor therapeutic response in FPHL, including pharmacogenetic factors, metabolic and endocrine comorbidities, treatment-related barriers, and advanced follicular miniaturization. Emerging evidence suggests that androgen receptor (AR) polymorphisms may influence antiandrogen responsiveness, whereas sulfotransferase (SULT1A1) activity may affect topical minoxidil efficacy. Obesity-related insulin resistance and polycystic ovary syndrome may further impair the follicular microenvironment through hyperandrogenism and chronic inflammation. Based on current evidence, we propose a practical three-step framework for evaluating poor responders: exclusion of pseudo-nonresponse, identification of metabolic-endocrine comorbidities, and incorporation of emerging biomarkers to support individualized treatment selection.
KEY MESSAGES: Poor therapeutic response in FPHL is multifactorial. Identifying the dominant contributing factor rather than simply escalating treatment intensity may facilitate precision management and improve outcomes in refractory patients.
SUMMARY: This review summarizes the major determinants of poor therapeutic response in FPHL, including pharmacogenetic factors, metabolic and endocrine comorbidities, treatment-related barriers, and advanced follicular miniaturization. Emerging evidence suggests that androgen receptor (AR) polymorphisms may influence antiandrogen responsiveness, whereas sulfotransferase (SULT1A1) activity may affect topical minoxidil efficacy. Obesity-related insulin resistance and polycystic ovary syndrome may further impair the follicular microenvironment through hyperandrogenism and chronic inflammation. Based on current evidence, we propose a practical three-step framework for evaluating poor responders: exclusion of pseudo-nonresponse, identification of metabolic-endocrine comorbidities, and incorporation of emerging biomarkers to support individualized treatment selection.
KEY MESSAGES: Poor therapeutic response in FPHL is multifactorial. Identifying the dominant contributing factor rather than simply escalating treatment intensity may facilitate precision management and improve outcomes in refractory patients.